99.7% PURITY LOT VL-2717-A BPC-157
A stable gastric pentadecapeptide supplied as a 5 mg lyophilized vial for research into tissue repair and gastrointestinal protection.
A higher-strength 10 mg lyophilized vial of the stable gastric pentadecapeptide BPC-157 for extended tissue-repair research.
- 1 × BPC-157 5mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
- 1 × BPC-157 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A stable gastric pentadecapeptide supplied as a 5 mg lyophilized vial for research into tissue repair and gastrointestinal protection.
- 5 mg lyophilized peptide per vial
- 15-amino-acid pentadecapeptide
- Synthetic peptide, ≥99% purity
- Studied for wound healing and gut protection
A higher-strength 10 mg lyophilized vial of the stable gastric pentadecapeptide BPC-157 for extended tissue-repair research.
- 10 mg lyophilized peptide per vial
- 15-amino-acid pentadecapeptide
- Synthetic peptide, ≥99% purity
- Higher strength for extended research protocols
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Technical data
Current lot snapshot
Shipping
Reported use in research
BPC-157 is a pentadecapeptide of 15 amino acids derived from a protective compound isolated from gastric juice. This 10 mg vial supports extended research into healing of muscle, tendon, and ligament, organ protection, and gastrointestinal integrity, where it acts systemically and promotes angiogenesis.
Reported findings
Reported research effects include accelerated reticulin and collagen formation, angiogenesis, and macrophage and fibroblast infiltration, alongside protection against gastrointestinal damage. Higher cumulative material supports longer or repeated-dosing protocols.
Handling & safety
BPC-157 has shown a favorable tolerability profile in animal research with low reported toxicity. Human clinical safety data remain limited and most evidence is preclinical.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 5.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 5.01 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 4.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 9.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 9.99 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 1419.556 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 10.02 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2717-A | Jul 2026 | 99.7% | TR-88789 | Sold out | |
| VL-2698-B | May 2026 | 99.6% | TR-88736 | Sold out | |
| VL-2679-C | Mar 2026 | 99.5% | TR-88535 | Sold out |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2941-A | Jul 2026 | 99.7% | TR-88069 | Sold out | |
| VL-2922-B | May 2026 | 99.6% | TR-88784 | Sold out | |
| VL-2903-C | Mar 2026 | 99.5% | TR-88583 | Sold out |
